Google Custom Search

Occult Hepatitis B Virus in Individuals without Liver Disease

Individuals infected with hepatitis B virus (HBV) typically either clear the virus completely or develop chronic disease. Some, however, have so-called "occult" or hidden HBV, characterized by low-level HBV DNA in the absence of detectable hepatitis B surface antigen (HBsAg).

This photograph is an electronmicroscopic image of hepatitis B virus particles.
According to the authors of a study described in the February 13, 2008 advance online edition of the Journal of Hepatology, occult HBV infection has been relatively well studied in patients with various hepatic disorders, but there is little information about cryptic infection in people without liver disease.

They therefore assessed the prevalence of occult HBV -- that is, detectable HBV DNA by polymerase chain reaction -- in the general population in Italy by examining liver specimens from 98 HBsAg negative individuals with no clinical or biochemical evidence of liver disease who underwent liver resection (partial removal) or needle biopsy during abdominal surgery.

Results
16 study participants were positive for hepatitis B core antibodies (anti-HBc), while 82 were negative for all HBV serum markers.

All were negative for hepatitis C virus (HCV) antibodies.

Occult HBV infection was detected in 16 of the 98 patients (16.3%).

Occult HBV was seen in 10 of 16 anti-HBc positive patients (63%) compared with 6 of 82 subjects (7%) without anti-HBc (P < 0.0001).

Conclusion

Based on these findings, the researchers concluded, "This study revealed that about 1/6 of the Italian general population might be carriers of occult HBV infection, and this condition is significantly associated with the anti-HBc positive status."

3/14/08

Reference
G Raimondo, G Navarra, S Mondello, and others. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. Journal of Hepatology. February 13, 2008 [Epub ahead of print]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


FDA-approved Combination Therapies for Chronic HCV Infection

Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin